The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. decreased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 7.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 74,247 shares of the medical device company’s stock after selling 5,902 shares during the period. Asset Management One Co. Ltd.’s holdings in Cooper Companies were worth $6,856,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Ashton Thomas Securities LLC acquired a new position in Cooper Companies during the third quarter worth approximately $25,000. Covestor Ltd grew its stake in shares of Cooper Companies by 144.9% in the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 200 shares during the last quarter. Byrne Asset Management LLC purchased a new position in shares of Cooper Companies in the 4th quarter valued at approximately $33,000. Brown Brothers Harriman & Co. grew its stake in shares of Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 275 shares during the last quarter. Finally, Cromwell Holdings LLC purchased a new position in shares of Cooper Companies in the 3rd quarter valued at approximately $52,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analyst Upgrades and Downgrades

COO has been the topic of several analyst reports. Citigroup lowered their target price on Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, December 6th. StockNews.com downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Wells Fargo & Company lifted their target price on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. Finally, Morgan Stanley decreased their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Cooper Companies has a consensus rating of “Moderate Buy” and an average target price of $117.00.

Cooper Companies Stock Performance

Shares of COO stock opened at $88.10 on Tuesday. The stock has a fifty day moving average price of $93.72 and a 200 day moving average price of $99.78. The stock has a market cap of $17.58 billion, a PE ratio of 45.18, a P/E/G ratio of 2.41 and a beta of 1.00. The Cooper Companies, Inc. has a 1 year low of $84.76 and a 1 year high of $112.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.04. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. Cooper Companies’s revenue was up 9.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.87 earnings per share. Sell-side analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.